Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: Improvement in pain and disability - A randomized, placebo-controlled, 3-month trial

Journal of Pain

Volumn 4, Issue 6, 2003, Pages 307-315

  Birbara, Charles A ^a   Puopolo, Anthony D ^b   Munoz, David R ^c   Sheldon, Eric A ^d   Mangione, Antoinette ^e   Bohidar, Norman R ^f   Geba, Gregory P ^f  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Milford Emergency Associates   (United States)

^c Internal Medicine   (United States)

^d MIAMI CANCER INSTITUTE   (United States)

^e ALBERT EINSTEIN MEDICAL CENTER   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chronic; Disability; Etoricoxib; Low back pain; Treatment

Indexed keywords

ETORICOXIB; PARACETAMOL; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC PAIN; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; LOW BACK PAIN; LOW BACK PAIN BOTHERSOMENESS SCALE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN ASSESSMENT; PATIENT AND INVESTIGATOR GLOBAL ASSESSMENT; PATIENT HEALTH SURVEY; PHASE 3 CLINICAL TRIAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY TRACT INFECTION; ROLAND MORRIS DISABILITY QUESTIONNAIRE; SYMPTOM; VISUAL ANALOG SCALE;

EID: 0042471727     PISSN: 15265900     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-5900(03)00633-3     Document Type: Article

References (37)

1. Atlas SJ, Deyo RA, Patrick DL, Convery K, Keller RD, Singer DE: The Quebec task force classification for spinal disorders and the severity, treatment, and outcomes of sciatic and lumbar spinal stenosis. Spine 21:2885-92, 1996
2. Bombardier C, Hayden J, Beaton DE: Minimally clinical important difference: low back pain: outcome measures. J Rheumatol 28:431-8, 2000
3. Borenstein DG: Chronic low back pain. Rheum Dis Clin North Am 22:439-56, 1996
4. Boyd IW, Mathew TH, Thomas MC: COX-2 inhibitors and renal failure: the triple whammy revisited. Med J Aust 173: 274, 2000
5. Brater DC, Harris C, Redfern JS, Gertz B: Renal effects of COX-2 selective inhibitors. Am J Nephrol 21:1-15, 2001
6. Buttgereit F, Burmester GR, Simon LS: Gastrointestinal toxic side effects on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. Am J Med 19(suppl 3A):13S-19S, 2001 110
7. Cannon GW, Breedveld FC: Efficacy of cyclooxygenase-2-specific inhibitors. Am J Med 19(suppl 3A):6S-12S, 2001 110
8. Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310:563-72, 1984
9. Cochrane DJ, Jarvis B, Keating GM: Etoricoxib. Drugs 62: 2637-51, 2002
10. Deyo RA, Battie M, Beurskens AJ, Bombardier C, Croft P, Koes B, Malmivaara A, Roland M, Von Korff M, Waldell G: Outcome measures for low back pain research: a proposal for standardized use. Spine 23:2003-2013, 1998
11. Deyo RA, Weinstein JN: Low back pain. N Engl J Med 344:363-370, 2001
12. Dionne CE, Von Korff M, Koepsell TD, Deyo RA, Barlow WE, Checkoway H: A comparison of pain, functional limitations, and work status indices as outcome measures in back pain research. Spine 24:2339-2345, 1999
13. Gandek B, Ware JE, Aaronson NK, Alonso J, Apolone C, Bjorner J, Ballinger M, Fukuhara S, Kaasa S, Leplege A, Sullivan M: Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 51:1171-1178, 1998
14. Hawkey CJ: Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 119:521-535, 2000
15. Hernandez-Diaz S, Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 160: 2093-2099, 2000
16. Jenkinson C, Layte R: Development and testing of the UK SF-12 (short form health survey). J Health Serv Res Policy 2:14-18, 1997
17. Koes BW, Scholten RJPM, Mens JMA, Bouter LM: Efficacy of non-steroidal anti-inflammatory drugs for low back pain: a systematic review of randomized clinical trials. Ann Rheum Dis 56:214-223, 1997
18. Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, Lines CR, Gertz BJ, Curtis S: A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 29:1623-1630, 2002
19. McCarthy DM: Comparative toxicity of non-steroidal anti-inflammatory drugs. Am J Med 107:37S-46S, 1999
20. Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxidase synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 268:6610-6614, 1993
21. Mitchel JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR: Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90:11693-11697, 1994
22. Nachemson AL: Newest knowledge of low back pain: a critical look. Clin Orthop 279:8-20, 1992
23. Noble SL, King DS, Olutade JI: Cyclooxygenase-2 enzyme inhibitors: place in therapy. Am Fam Physician 61:3669-3676, 2000
24. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low back pain. Phys Ther 81.1641-1674, 2001.
25. Riddle DL, Lee KT, Stratford PW: Use of SF-36 and SF-12 health status measures: a quantitative comparison for groups versus individual patients. Med Care 39:867-878, 2001
26. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay P, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresses M, Ford-Hutchinson AW, Young RN, Chan CC: Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296:558-566, 2001
27. Roland M, Morris R: A study of the natural history of back pain: part 1: development of a reliable and sensitive measure of disability in low-back pain. Spine 8:141-144, 1983
28. Simon LS: Role and regulation of cyclooxygenase-2 during inflammation. Am J Med 106:37S-42S, 1999
29. van Tulder MW, Scholten RJPM, Koes BW, Deyo RA: Non-steroidal anti-inflammatory drugs for low back pain: a systematic review within the framework of the Cochrane collaboration back review group. Spine 25:2501-2513, 2000
30. Verburg KM, Maziasz TJ, Weiner E, Loose L, Geis GS, Isakson PC: Cox-2-specific inhibitors: definition of a new therapeutic concept. Am J Ther 8:49-64, 2001
31. Ware JE Jr, Kosinski M, Keller SD: A 12-Item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220-233, 1996
32. Watson DJ, Harper SE, Zhao PJ, Quan H, Bolognese JA, Simon TJ: Gastrointestinal tolerability of the selective cyclooxygenase-2 (Cox-2) inhibitor rofecoxib compared with non-selective Cox-1 and Cox-2 inhibitors in osteoarthritis. Arch Int Med 160:2998-3003, 2000
33. Weaver AL: Rofecoxib: clinical pharmacology and clinical experience. Clin Ther 23:1323-1338, 2001
34. Winkelstein BA, Weinstein JN, DeLeo JA: The role of mechanical deformation in lumbar radiculopathy: an in vivo model. Spine 27:27-33, 2002
35. Wipf JE, Deyo RA: Low back pain. Med Clin North Am 79:231-246, 1995
36. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal tolerability of nonsteroidal anti-inflammatory drugs. N Engl J Med 340:1888-1899, 1999
37. Zigmond A, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370, 1983